TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …

Abstract Endometrial cancer accounts for~ 76,000 deaths among women each year
worldwide. Disease mortality and the increasing number of new diagnoses make …

Endometrial cancer is the most commonly diagnosed gynecologic malignancy in the United
States. Endometrioid endometrial carcinomas constitute approximately 85% of newly …

Loading drugs into carriers such as liposomes can increase the therapeutic ratio by
reducing drug concentrations in normal tissues and raising their concentrations in tumors …

Ovarian cancer is the most lethal gynecological malignancy, with an alarmingly poor
prognosis attributed to late detection and chemoresistance. Initially, most tumors respond to …

Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is
characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective …

Prolonged obstruction of the ureter, which leads to injury of the kidney collecting ducts,
results in permanent structural damage, while early reversal allows for repair. Cell structure …

Individual mutations in the tumor suppressor TP53 alter p53 protein function. Some
mutations create a non-functional protein, whereas others confer oncogenic activity, which …

Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer that has not
been well characterized. It accounts for less than 10% of all endometrial cancers and 80% of …

The repair of DNA damage caused by chemotherapy in cancer cells occurs mainly at two
cell cycle checkpoints (G 1 and G 2) and is a factor contributing to chemoresistance. Most …